Patents by Inventor Ayodeji Abdur-Rasheed Asuni

Ayodeji Abdur-Rasheed Asuni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 11739140
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: August 29, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20220177557
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: August 11, 2021
    Publication date: June 9, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 11111290
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 7, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20210206843
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 8, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Antibodies specific for hyperphosphorlated tau for the treatment of ocular diseases
    Patent number: 10995137
    Abstract: The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and their tau binding fragments in the treatment of retinoid amyloidosis, age related macular degeneration (ARMD), and glaucoma.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: May 4, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10934348
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: March 2, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20200190178
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: December 20, 2019
    Publication date: June 18, 2020
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20200109192
    Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
    Type: Application
    Filed: September 27, 2019
    Publication date: April 9, 2020
    Inventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10562962
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: February 18, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORLATED TAU FOR THE TREATMENT OF OCULAR DISEASES
    Publication number: 20190330320
    Abstract: The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and their tau binding fragments in the treatment of retinoid amyloidosis, age related macular degeneration (ARMD), and glaucoma.
    Type: Application
    Filed: January 3, 2018
    Publication date: October 31, 2019
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist
  • ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
    Publication number: 20190177401
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: November 13, 2018
    Publication date: June 13, 2019
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Antibodies specific for hyperphosphorylated tau and methods of use thereof
    Patent number: 10196439
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: February 5, 2019
    Assignee: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Christiane Volbracht, Lone Helboe, Anders Brandt Elvang, Florence Sotty, Søren Christensen, Jeffrey B. Stavenhagen
  • Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof
    Publication number: 20170015738
    Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.
    Type: Application
    Filed: July 12, 2016
    Publication date: January 19, 2017
    Applicant: H. Lundbeck A/S
    Inventors: Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Alfred Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist